News Home

Should You Buy Alcon AG (ALC) Stock After it Is Down 0.28% in a Week?

Friday, October 15, 2021 01:59 PM | InvestorsObserver Analysts
Should You Buy Alcon AG (ALC) Stock After it Is Down 0.28% in a Week?

Alcon AG (ALC) stock has fallen 0.28% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Alcon AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALC!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ALC Stock Today?

Alcon AG (ALC) stock is trading at $78.28 as of 1:55 PM on Friday, Oct 15, a loss of -$0.53, or -0.67% from the previous closing price of $78.80. The stock has traded between $78.26 and $78.67 so far today. Volume today is low. So far 351,105 shares have traded compared to average volume of 646,690 shares.

More About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. Click Here to get the full Stock Report for Alcon AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App